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2013, accepted Janotropes have been fundamental to resuscitation of acute cardiogenic shock for decades. Heart failure and
cardiogenic shock, in severe cases, are syndromes characterized in many patients by a reduction in myocardial
contractile force. While inotropes successfully increase cardiac output, their use has been plagued by excessive
mortality due to increased tachycardia and myocardial oxygen consumption leading to arrhythmia and myocardial
ischemia. There is a pressing need for new inotropic agents that avoid these harmful effects. This review describes
the mechanism of action and the clinical utility of some of the older inotropic agents, which are still commonly used,
and provides an update for physicians on the development of newer inotropic drugs. The ﬁeld is rapidly changing,
and it is likely that new agents will be designed that improve systolic performance without necessarily increasing the
myocardial oxygen consumption. (J Am Coll Cardiol 2014;63:2069–78) ª 2014 by the American College of
Cardiology FoundationPositive inotropic agents have been used to treat patients
with heart failure since 1775 when Withering introduced
foxglove into practice. Inotropic drugs may be strictly de-
ﬁned as therapies that enhance myocardial contractile per-
formance independent of changes in heart rate and loading
conditions. However, loading conditions and heart rate are
highly variable in patients with heart failure; they are subject
to change, and may be altered by some inotropic drugs.
Many inotropic drugs increase heart rate, and some have
direct or indirect vasodilator properties. Therefore, some of
the improved systolic performance generated by inotropic
agents may also be due to changes in loading conditions
and heart rate inherent to many of these drugs.
Today, positive inotropic drugs are typically used to sta-
bilize patients with acute decompensated heart failure in the
intensive care unit, as a bridge to heart replacement therapy,
or a bridge-to-decision. Intravenous positive inotropic drugs
are indicated when patients with acute systolic heart failure
exhibit signs or symptoms of end-organ dysfunction due
to hypoperfusion (1). The use of positive inotropic drugs
has been plagued by serious concerns regarding increased
morbidity and mortality. Problems include increased arrhy-
thmia, induced myocardial ischemia, and in some cases,
hypotension (2–7). The largest database demonstrating in-
creased mortality with inotropes is the ADHERE (Acute
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uary 14, 2014.short-term inotropic therapy was associated with increased
in-hospital mortality (8).
Despite clear evidence that inotropic therapy increases
mortality, there are clinical settings where inotropic support
with dopamine, dobutamine, milrinone, or norepinephrine
may be life-saving measures. For example, short-term use of
intravenous positive inotropic drugs may have a clear ther-
apeutic role in patients hospitalized with acute systolic heart
failure, where hypoperfusion of vital organs is obvious and
the need for improved perfusion is immediate. Although
temporary mechanical circulatory support devices (intra-
aortic balloon pumps, extracorporeal membrane oxygena-
tion, impella, and others) are now available to augment
cardiac output and blood pressure, these short-term and less
durable devices are reserved for special circumstances such as
bridge-to-heart replacement therapy or bridge-to-decision
(9). In some cases, such as in the setting of acute myo-
cardial infarction, short-term, less durable devices are also
implanted for temporary support while awaiting revascular-
ization, but stabilization therapy often begins with intrave-
nous inotropic agents.
Some patients require sustained inotropic support, as
they cannot be weaned from drugs such as dobutamine or
milrinone without experiencing hypoperfusion. Such pati-
ents are believed to be “inotrope-dependent” when repeated
attempts to wean result in symptomatic hypotension, wor-
sening symptoms, and/or progressive organ dysfunction
(usually renal). Further use of inotropic agents should not
be based on hemodynamic parameters alone but on clinical
deterioration. Inotropic therapy is appropriate in hospital-
ized patients with evidence of end-organ hypoperfusion
until resolution of the acute cause occurs and in situations
requiring chronic critical support until deﬁnitive therapy
such as heart transplantation, mechanical circulatory support,
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2070or bridge-to-decision. For those
patients who are not candidates
for advanced heart replacement
therapy, intravenous inotropesmay
also be considered as palliation at
the end of life.
With this in mind, cardiolo-
gists should be familiar with
the pharmacology of conventional
positive inotropic agents and how
the drugs’ use might be applied
under various circumstances. For
example, patients with ischemic
cardiomyopathy and decompen-
sated heart failure who are ex-
periencing ongoing angina orrhythm disturbances would be poor candidates for pharma-
cologic inotropic support. Such patients are perhaps best
managed by direct coronary revascularization in the car-
diac catheterization laboratory when possible. Even pati-
ents with chronic ischemic cardiomyopathy without active
symptoms of coronary artery disease are at substantial
risk when given drugs that increase myocardial oxygen de-
mand. Other strategies including mechanical circulatory
devices such as an intra-aortic balloon pump may be more
appropriate than using large doses of norepinephrine,
dopamine, dobutamine, or milrinone. In addition, new in-
otropic agents that use noncatecholamine pathways are
being developed, thereby adding positive inotropy without
necessarily increasing myocardial oxygen consumption. In
this article, we review the history of some of the older agents
and provide an update for physicians on the development
of new drugs.
Conventional Inotropic Agents
The positive inotropic drugs that are widely used in the
United States include digoxin, dopamine, dobutamine,
milrinone, and norepinephrine.
Digoxin. There is still considerable debate regarding the
role of digoxin for the treatment of patients with systolic
heart failure. Although digoxin is generally considered to be
a positive inotropic agent, there is uncertainty regarding
the precise mechanisms whereby digoxin improves heart
failure. We know that digoxin improves hemodynamics
without adversely affecting heart rate or blood pressure (10).
It tends not to increase myocardial oxygen demand and
does not reduce coronary perfusion. It further diminishes
neurohormonal activation (11–13), does not impair kidney
function, and is available in both intravenous and oral form.
Perhaps most importantly, digoxin can improve symptoms
and tends to reduce hospitalization rate (14). When digoxin
is withdrawn from patients with stable heart failure, there
is considerable risk that patients will clinically deteriorate
(15,16). Digoxin also improves hemodynamics at rest and
during exercise (17). Importantly, digoxin is cleared by renalexcretion, making accumulation problematic in patients with
impaired renal function.
Despite the fact that we have known about molecular
targets for cardiac glycosides for several decades, it remains
uncertain whether the sympatholytic or positive inotropic
effects are responsible for relief of symptoms in heart failure
(18). Digoxin acts by inhibiting the sarcolemmal Naþ/Kþ
ATPase pump, thereby impeding the transport of sodium
from the intracellular to the extracellular space. The reduc-
tion in the transmembrane sodium gradient tends to further
reduce the activity of the Naþ/Ca2þ exchanger, thereby
raising the intracellular calcium levels (Fig. 1). It is now
believed that the increase in activator calcium is responsible
for both the inotropic and the arrhythmogenic effects of
cardiac glycosides. Digoxin has been used to wean patients
dependent on intra-aortic balloon pumps or inotropic sup-
port (19). Digoxin was once widely used to treat patients
with systolic heart failure. However, in 1997, results from
the DIG (Digitalis Investigation Group) study indicated
that digoxin had a neutral effect on mortality, although re-
ductions were seen in overall rates of hospitalization and
heart failure progression (20). The 15 years that followed the
DIG study have seen a substantial decrease in its use for the
treatment of heart failure. However, we believe there is still
a role for digoxin in patients with heart failure (21).
Digoxin is particularly useful for patients with heart
failure and concomitant atrial ﬁbrillation, where it helps to
control the heart rate. Atrial ﬁbrillation occurs in roughly
20% to 30% of patients with heart failure, but the prevalence
varies widely. A lenient rate control strategy targeting a
ventricular rate of <110 beats/min is a preferred therapeutic
pathway (22). However, cardioversion is sometimes neces-
sary in the case of hemodynamic instability or refractory
symptoms. Although intravenous diltiazem or verapamil
are widely used to slow rapid atrial ﬁbrillation, these two
drugs can be problematic in patients with moderate hypo-
tension or severe left ventricular (LV) dysfunction. In this
scenario, small repeated doses of intravenous digoxin may be
preferred.
The DIG trial also demonstrated the importance of
measuring digoxin levels. Digoxin levels 1.2 ng/ml may be
harmful; whereas, levels in the range of 0.5 to 0.9 ng/ml may
be optimal. In general, digoxin levels below 1.0 ng/ml are
safer and may even be more effective (1,23–25). A post-hoc
subgroup analysis of the DIG study indicated that the effects
of digoxin vary between men and women (26). Digoxin was
associated with an increase in all-cause mortality among
women, but not men, with systolic heart failure. It is
conceivable that women, because they tend to have lower
body weight, may be more prone to harmful elevations of
digoxin levels (1.2 ng/ml) (27).
Dopamine. Dopamine, the immediate precursor to nor-
epinephrine in the catecholamine synthetic pathway, is an
endogenous neurotransmitter with multiple clinically im-
portant effects (28). Use of exogenous dopamine was largely
studied and developed in the laboratories of Leon Goldberg
Figure 1 Diagram of Intracellular Signaling Cascades Within Cardiomyocytes Altered by Inotropes
Dopamine, dobutamine, and norepinephrine activate the b1-adrenergic receptor, which activates the G protein Gas, which in turn, activates adenylyl cyclase. Adenylyl cyclase
converts ATP to cAMP when activated. cAMP can activate PKA, which then phosphorylates the L-type calcium channel, among other targets. cAMP is converted to AMP by PDE.
Milrinone inhibits PDE-3 thereby increasing the effective concentration of cAMP. Calcium inﬂux through the L-type calcium channel induces activation of ryanodine receptors,
leading to calcium-induced calcium release. Free intracellular calcium interacts with troponin C, which changes the binding properties of tropomyosin and allows the interaction
between actin and myosin. Levosimendan potentiates the interaction between troponin and calcium. It may also have PDE-3 inhibitor activity as well. Omecamtiv mecarbil
increases the rate of ATP turnover and slows the rate of ADP release thereby increasing the number of myosin molecules bound to actin at any given time. SERCA is responsible
for uptake of calcium into the sarcoplasmic reticulum while the Na/K ATPase participates in resetting the membrane potential of the cell. Istaroxime inhibits Na/K ATPase while
also potentiating SERCA. Digoxin inhibits the Na/K ATPase. Red arrows denote agonists, whereas black arrows signify antagonists. AC ¼ adenylyl cyclase; ADP ¼ adenosine
diphosphate; ATP ¼ adenosine triphosphate; B1AR ¼ b1-adrenergic receptor; cAMP ¼ cyclic adenosine monophosphate; LTCC ¼ L-type calcium channel; PDE ¼ phospho-
diesterase; PKA ¼ protein kinase A; RyR ¼ ryanodine receptor; SERCA ¼ sarco/endoplasmic reticulum Ca2þ-ATPase.
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2071at the University of Chicago. It has been used intravenously
to treat cardiogenic and septic shock since the 1970s. At
low doses (<3 mg/kg/min), dopamine activates dopami-
nergic (D1) receptors that subserve vasodilation in various
vascular beds, including the coronary and renal arteries.
Despite the early observation demonstrating increased renal
blood ﬂow (28), the beneﬁts of “renal doses” of dopamine
have remained controversial. Estimated glomerular ﬁltra-
tion rate does not improve with use of low-dose dopamine
infusions, and there is no apparent renal protective effect
(29). The ROSE AHF (Renal Optimization Strategies
Evaluation in Acute Heart Failure) trial recently found
that neither nesiritide nor low-dose dopamine was better
than placebo when added to standard care (30). It is pos-
sible that some patients may experience inotropic effects
even at low doses of dopamine. Intermediate doses of
dopamine (3 to 10 mg/kg/min) activate b-adrenergic re-
ceptors that cause increased inotropy and heart rate and also
promote release and inhibit reuptake of norepinephrine in
presynaptic sympathetic nerve terminals (Fig. 1). At higher
infusion rates (10 to 20 mg/kg/min), dopamine acts pri-
marily as an a-adrenergic agonist resulting in peripheral
vasoconstriction.Dobutamine. Dobutamine was introduced in the late
1970s as a new, synthetic, intravenously administered cate-
cholamine that had a direct agonist effect on b1- and b2-
adrenergic receptors with no vasoconstrictor properties and
less tachycardia (Fig. 1) (31). This drug was developed in
the laboratories of Eli Lilly under the direction of Dr. Ron
Tuttle. Many of the early human studies were performed
in the laboratories of Dr. Carl Leier at Ohio State Univer-
sity. In principle, it was suggested that dobutamine might
have an advantage over dopamine, as it does not increase
sympathetic norepinephrine signaling or peripheral vaso-
constriction (32). Dobutamine raises blood pressure solely
by increasing cardiac output, whereas dopamine raises
blood pressure via peripheral vasoconstriction (33). Both
dobutamine and dopamine can reduce left ventricular end-
diastolic pressure (LVEDP), although dopamine has the
propensity to raise afterload when used in high doses and
theoretically could increase ﬁlling pressure. Dobutamine can
reduce blood pressure in some patients due to the peripheral
vasodilatory properties, but the severity and importance of
this effect varies widely among patients. Dobutamine can
also cause idiosyncratic adverse effects including eosinophilia
(34,35) and fever (36).
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2072Dobutamine quickly became a popular drug to treat pa-
tients with severe heart failure, as it clearly improves cardiac
output and lowers LVEDP with only a modest increase in
heart rate (37). It exhibits a peripheral vasodilatory effect,
most likely caused by b2-adrenergic stimulation in the pe-
ripheral vasculature in combination with reﬂex withdrawal
of intense vasoconstriction. With time and experience,
however, it became clear that dobutamine infusions lasting
longer than 72 h were associated with pharmacodyna-
mic tolerance (38). Tachycardia, myocardial ischemia, and
arrhythmia can occur during dobutamine infusions, espe-
cially at doses of 15 mg/kg/min or higher. Generally, these
outcomes are rapidly reversible, as the plasma half-life is
2.37  0.7 min (32), indicating that >98% of the drug is
eliminated within 10 to 12 min after cessation of the
infusion.
Initial studies by Leier et al. (39) indicated that dobut-
amine improved regional blood ﬂow to skeletal muscles
and other regional beds. Subsequent metabolic studies by
Mancini et al. (40) using phosphorous-31 magnetic reso-
nance spectroscopy demonstrated that even though dobut-
amine improves the overall blood ﬂow to the limb, it is
unlikely to improve oxygen delivery to working skeletal
muscle.
During the early stages of dobutamine use, a potential
durable clinical beneﬁt of short-term infusion was observed
(41,42). Short-term infusion for 72 h selectively improves
vascular endothelial function for 2 weeks (43). These ob-
servations led to the use of chronic home or outpatient in-
fusions of dobutamine (44–46). However, the tide turned
when it became clear that infusion of dobutamine for 7 to
52 days (median duration, 14 days) at an average dose of
9 mg/kg/min was associated with a much higher 6-month
mortality compared with a vasodilator, epoprostenol (47).
In the FIRST (Flolan International Randomized Survival
Trial), dobutamine was associated with worse survival and
poorer clinical outcomes and did not improve quality of
life during or after the infusions. Although the data were
observational, subsequent experience has veriﬁed that use of
inotropic therapy for the treatment of severe heart failure is
associated with reduced survival. Long-term infusions are
still used as a bridge to heart replacement therapy and also
in the palliative care setting.
Norepinephrine. Norepinephrine is an endogenous cate-
cholamine normally synthesized, stored, and released from
sympathetic neurons. Norepinephrine has potent a- and b-
adrenergic receptor agonist properties including increased
chronotropy, heightened inotropy, and increased peripheral
vasoconstriction (Fig. 1). Synthetically manufactured nor-
epinephrine has been available for decades for the treatment
of severe septic and cardiogenic shock. Similar to high-dose
dopamine, it should be given through a secure intravenous
cannula or, preferably, a central venous catheter because of
its potential to cause skin necrosis and sloughing of tissue.
Typically, norepinephrine is infused at 0.2 to 1 mg/kg/min.
As with all catecholamine-based therapies, it can beassociated with tachycardia, myocardial ischemia, and
arrhythmia. There is a large experience with the drug over
many years. However, high doses of dopamine (>3 mg/kg/
min) seem equivalent to those of norepinephrine with
similar attributes and adverse effects. A comparator study
published in 2010 indicated that a subset of patients with
cardiogenic shock derived more survival beneﬁt from nor-
epinephrine than from dopamine (48). However, it should
be noted that the study included patients with various types
of shock, that the overall mortality rate was similar between
dopamine and norepinephrine, and that there were more
adverse effects with the use of dopamine than with the use of
norepinephrine.
It has been noted that occasionally patients in cardiogenic
shock present with vasodilation and hypotension. We have
also commonly seen patients develop refractory vasodilation
following mechanical circulatory assist device implantation.
Such patients beneﬁt from vasoconstricting agents such as
norepinephrine, although intravenous arginine vasopressin
has also been successfully used (49,50).Nonadrenergic Inotropic Agents
Milrinone. Milrinone is a bipyridine, noncatecholamine,
positive inotropic agent that can be given intravenously to
patients with advanced systolic heart failure to improve
cardiac performance (51). It is both a positive inotropic
agent and a peripheral vasodilator. Milrinone also has lusi-
tropic properties which are manifested by improvement in
diastolic function. It raises heart rate, but not to the same
extent as dobutamine. This is because dobutamine has direct
b-adrenergic receptor activity. Milrinone, on the contrary,
is a phosphodiesterase (PDE) inhibitor (Fig. 1). It inhibits
PDE-3, an intracellular enzyme that breaks down cyclic
adenosine monophosphate (cAMP). cAMP is a second
messenger that modulates intracellular calcium. PDE-3 in-
hibitors thus increase cAMP, which increases calcium entry
into the cardiac myocytes as well as the rate of removal,
which in turn leads to increased myocardial contractility. In
vascular smooth muscle, heightened cAMP primarily in-
creases removal of calcium from the vascular smooth muscle
cell, leading to cellular relaxation and vasodilation. Milri-
none was introduced in the early 1990s for the treatment of
severe systolic heart failure.
Based on the lack of head-to-head trials, there is no
preference for milrinone versus dobutamine in most patients.
Because activation of b1-receptors increases cAMP similar
to milrinone, the downstream effects of the drugs are likely
similar. However, milrinone may be the preferred inotropic
drug for patients receiving b-adrenergic blocking drugs, as
it does not use the b-adrenergic receptor to drive cardiac
contractility, unlike dobutamine and dopamine. It is also
favored in some patients who have markedly elevated pul-
monary artery pressure. Milrinone, through its enhancement
of cAMP, may reduce pulmonary artery pressure via a
vasodilator mechanism and, therefore, may improve right
JACC Vol. 63, No. 20, 2014 Francis et al.
May 27, 2014:2069–78 Inotropes
2073ventricular function. The use of PDE-5 inhibitors for pul-
monary hypertension and right ventricular failure is currently
under intense study, but these agents are considered vaso-
dilators and not positive inotropic agents. Dobutamine and
milrinone lead to similar increases in cardiac output and
decreases of ﬁlling pressure, although milrinone may reduce
LV ﬁlling pressure more than dobutamine. However, mil-
rinone can lead to hypotension, especially in patients with
low ﬁlling pressure. It should be avoided in patients with
impaired renal function, as milrinone is renally cleared. It
has a relatively long plasma elimination half-life (50 min,
although this may be longer in severe heart failure). If hy-
potension or arrhythmia occurs, these adverse effects may
persist for hours (52). A bolus infusion can sometimes cause
hypotension and is not recommended. An initial continuous
infusion dose of 0.125 mg/kg/min is generally reasonable.
In the OPTIME-CHF (Outcomes of Prospective Trial
of Intravenous Milrinone for Exacerbations of Chronic
Heart Failure), there was no support for the use of intra-
venous milrinone as an adjunct to standard therapy for
hospitalized patients treated with an exacerbation of chronic
heart failure (5). Sustained hypotension with milrinone was
more common than with placebo (10.7% vs. 3.2%), and
occurrence of atrial arrhythmias was also more common
(4.6% vs. 1.5%) (5). In-hospital mortality was similar be-
tween milrinone and placebo (3.8% vs. 2.3%). These ﬁnd-
ings run counter to earlier observational studies that were
more favorable toward milrinone (53). Despite the fact that
dobutamine increases myocardial oxygen consumption and
milrinone may not (54), this seems not to be a distinguishing
or clinically important attribute of milrinone. There is a
belief that the harm of inotropic agents is not due solely to
effects on myocardial oxygen consumption but may be
related to the increase in intracellular calcium as a conse-
quence of heightened cAMP in the cell. Although the 2 are
linked, it is not absolutely clear that all of the harm is entirely
related to heightened myocardial oxygen consumption. An
increase in mortality was also seen with chronic use of oral
milrinone in patients with severe chronic heart failure (55).
Routine outpatient infusion of milrinone (and dobutamine)
is to be discouraged. However, long-term use as a bridge to
heart replacement therapy or as a form of palliative care
when other therapies are insufﬁcient may be appropriate.
Milrinone remains widely used to treat patients with acute
decompensated heart failure and in our view should be
considered speciﬁcally for patients who have preserved renal
function or pulmonary hypertension or patients who are
receiving a b-adrenergic blocking agent.
Levosimendan. Levosimendan is a calcium sensitizing
drug widely used in Europe but is not approved for use in
the United States. The drug appears to enhance troponin C
sensitivity to intracellular calcium, thereby enhancing cardiac
inotropy and lusitropy (56). Levosimendan also causes pe-
ripheral vasodilation by opening smooth muscle adenosine
triphosphate (ATP)-dependent potassium channels. It may
also have some PDE-3 inhibitor activity (57).Calcium sensitizing agents such as levosimendan exert
positive inotropic effects on the heart by increasing the
contractile apparatus’ sensitivity to calcium (58). Therefore,
such drugs have the theoretical advantage of driving con-
tractile state without increasing cAMP or calcium itself,
both of which have adverse effects. It appears that levosi-
mendan’s ability to enhance calcium responsiveness of
myoﬁlaments potentiates cross-bridge formation, thereby
augmenting contractility and enhancing relaxation (59).
Levosimendan causes a rapid dose-dependent improvement
in the deranged hemodynamic proﬁle of patients with severe
heart failure (60). Typically the dose is titrated upward over
4 h from 0.1 mg/kg/min to 0.4 mg/kg/min and is maintained
for several hours. Symptoms appear to improve.
There have been 2 randomized trials with levosimendan:
REVIVE-II (Randomized Multicenter Evaluation of In-
travenous Levosimendan Efﬁcacy) (61) and SURVIVE
(Survival of Patients with Acute Heart Failure in Need of
Intravenous Inotropic Support) (7). The REVIVE-II study
indicated no difference in mortality at 90 days, although
survival was not a primary end point, and levosimendan was
associated with more adverse effects. In SURVIVE, levosi-
mendan was compared with dobutamine in a randomized,
controlled trial involving 1,327 patients. In the trial, levo-
simendan did not signiﬁcantly reduce all-cause mortality at
180 days and did not affect any secondary clinical outcomes
(7). Levosimendan was associated with more peripheral
vasodilation and hypotension than dobutamine. In a smaller
hemodynamic study, levosimendan improved hemodynamic
performance more effectively than dobutamine (6). Few data
are available regarding oral levosimendan, but at least one
study indicated improved quality of life scores with oral
levosimendan (62).
New and Emerging Positive Inotropic Agents
The quest to develop more effective and safer positive
inotropic drugs has continued despite numerous setbacks
and disappointments. Some new agents do not target ino-
tropy per se. Additional targets may include improved
mitochondrial function through modulation of oxidative
stress, iron handling, and biogenesis (63). Newer positive
inotropic agents will also have greater advantages if they can
be given orally.
Omecamtiv mecarbil. Formerly known as CK-1827452,
omecamtiv mecarbil was developed by Malik et al. (64) at
Cytokinetics, and it has emerged as an interesting new po-
tential therapy for heart failure (65). Omecamtiv mecarbil is
the ﬁrst selective cardiac myosin activator to be studied in
humans (66). It is under intense investigation in the labo-
ratories of John Teerlink and others.
The small omecamtiv mecarbil molecule increases the
efﬁciency of heart muscle contraction via selectivity for a
subset of cardiac myosins. It does not affect fast isoforms of
myosin in other organs. Myosin motors act on the thin ﬁl-
aments via the actin and troponin-tropomyosin complex.
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2074The chemical energy necessary to drive myosin movement
is derived from ATP hydrolysis. As a selective allosteric
activator of cardiac myosin, omecamtiv mecarbil’s action
depends on “activation” rather than enzyme inhibition.
Omecamtiv mecarbil selectively activates the S1 domain
of cardiac myosin, the main component of the thick sar-
comeric ﬁlament. Omecamtiv mecarbil increases the rate
of ATP turnover by accelerating actin-dependent phos-
phate release and by slowing the rate of adenosine 50-
diphosphate (ADP) release. This increases the occupancy
time of myosin on actin, leading to increased numbers of
myosin molecules bound to actin, which causes prolonga-
tion of the contractile force without increasing left ven-
tricular pressure development (dP/dt) (Fig. 2) (64,67,68).
The calcium transient remains unchanged with omecamtiv
mecarbil in contrast to conventional inotropic agents such
as dobutamine, which increase intracellular cAMP and
thereby increase the calcium transient. By this mechanism,
it appears that omecamtiv mecarbil does not increase the
heart’s demand for energy, rather, it improves systolic per-
formance by allowing the myocardium to make more efﬁ-
cient use of energy (67).
Sufﬁcient data were provided from a phase II dose-
ranging trial in 45 patients with stable heart failure to
initiate a new trial, ATOMIC AHF (Acute Treatment with
Omecamtiv Mecarbil to Increase Contractility–Acute Heart
Failure; NCT01300013). The ATOMIC AHF trial results
were recently presented at the European Society of Cardi-
ology (Amsterdam, 2013), and the drug appears to avoid the
usual adverse effects (e.g., tachycardia and arrhythmia) of
traditional inotropic agents. Early experience demonstrated
an increase in LV ejection fraction and stroke volumeFigure 2
Time-Dependent LV End Systolic Elastance, a Load-Indepen
Dobutamine and Omecamtiv Mecarbil
The responses for each dog to dobutamine (10 mg/kg/min) and omecamtiv mecarbil (10
elastance at baseline to compare the shapes of the responses. From Malik et al. (64).with decreased end-systolic and end-diastolic volumes. At
high plasma concentrations, chest pain, tachycardia, and
myocardial ischemia were noted (69).
On balance, the development of omecamtiv mecarbil is
an example of highly creative biological engineering used to
produce a molecule that can improve myocardial perfor-
mance by prolonging systole rather than increasing the ve-
locity of ﬁber-shortening, which is the mechanism typical
of most positive inotropic agents. Omecamtiv mecarbil does
not appear to drive oxygen consumption like more con-
ventional agents, which is a unique attribute. In a sense,
omecamtiv mecarbil may not be an inotrope, but it does
improve myocardial systolic performance. Omecamtiv mecar-
bil has moved from the laboratory to clinical trials on a
relatively rapid trajectory. We await the results of additional
clinical studies with anticipation.
Sarcoplasmic Reticulum Ca2D-ATPase Modulation
Calcium is critical in regulating the contraction and relaxa-
tion phases of the cardiac cycle. Sarcoplasmic reticulum
Ca2þ-ATPase (SERCA2a) is an enzyme responsible for
both myocardial relaxation by reuptake of calcium into
the sarcoplasmic reticulum (SR) and contractility by con-
trolling the amount of calcium in the SR (70). SERCA2a
is downregulated in the failing human heart, resulting
in contractile dysfunction and arrhythmia (71). Experi-
mental animal models of heart failure have demonstrated
an improvement in contractility, cardiac metabolism, and
survival when SERCA2a expression is increased in car-
diomyocytes leading to restoration of intracellular calcium
cycling (72).dent Measure of Cardiac Contractility Plot for
min following a 1 mg/kg bolus) were normalized to the magnitude and time of peak
Table 1 Inotropic Drugs: Mechanisms and Outcomes
Drug Mechanism Effect on Mortality Key Trials (Ref. #)
Digoxin Na-K pump inhibitor, raises SR calcium Neutral, increased mortality if long-term
therapy discontinued
DIG (15,20)
Dopamine Dose-dependent D1, a1-, and b1-adrendergic receptor agonist Increased (48)
Norepinephrine b1- and a1-adrenergic receptor agonist Increased (48)
Dobutamine b1- and b2-adrenergic receptor agonist Increased FIRST (47)
Milrinone PDE inhibitor, raises SR calcium Increased OPTIME-CHF (5)
Levosimendan Myoﬁlament calcium sensitizer, PDE-3 inhibitor Neutral REVIVE-II (61),
SURVIVE (7)
Omecamtiv
mecarbil
Potentiates the effects of myosin on actin to prolong systole Unknown ATOMIC AHF (underway),
(66,69)
Istaroxime Na-K pump inhibitor, PDE inhibitor Unknown HORIZON-HF (75)
SERCA2a gene
therapy
Restoration of SERCA2a to improve calcium release and
reuptake from the SR
Unknown CUPID (70)
Studies: ATOMIC AHF ¼ Study to Evaluate the Safety and Efﬁcacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure;
CUPID ¼ Calcium Up-regulation by Percutaneous administration of gene therapy In cardiac Disease; DIG ¼ Digitalis Investigation Group; FIRST ¼ Flolan International Randomized Survival Trial; HORIZON-
HF ¼ Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart
Failure; OPTIME-CHF ¼ Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure; REVIVE-II ¼ Randomized Multicenter Evaluation of Intravenous Levosimendan
Efﬁcacy; SURVIVE ¼ Survival of Patients with Acute Heart Failure in Need of Intravenous Inotropic Support.
AC ¼ adenylyl cyclase; ADP ¼ adenosine diphosphate; ATP ¼ adenosine triphosphate; B1AR ¼ b1-adrenergic receptor; cAMP ¼ cyclic adenosine monophosphate; LTCC ¼ L-type calcium channel; PDE ¼
phosphodiesterase; PKA ¼ protein kinase A; RyR ¼ ryanodine receptor; SERCA ¼ sarco/endoplasmic reticulum Ca2þ-ATPase.
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2075The ﬁrst clinical trial of gene therapy for heart failure in
the United States was CUPID (Calcium Up-regulation by
Percutaneous administration of gene therapy In car-
diac Disease). The trial was a multicenter open-label study
designed to evaluate the safety proﬁle and provide ﬁrst-
in-human data for the gene transfer of SERCA2a cDNA
(adeno-associated virus [AAV1]/SERCA2a). The cDNA
was delivered by intracoronary infusion. The phase I dose
escalation portion of the study demonstrated an adequate
safety proﬁle in patients with advanced heart failure (73,74).
In phase II of the CUPID study, 39 patients with ad-
vanced heart failure (estimated 1-year mortality rate of 25%)
were randomly allocated to intracoronary AAV1-mediated
SERCA2a gene delivery or placebo (70). Clinical efﬁcacy
was assessed using symptoms (New York Heart Association
class and Minnesota Living With Heart Failure Question-
naire), walking distance (6-min walk test, maximal oxygen
consumption [VO2max]), biomarkers (N-terminal pro-brain
natriuretic peptide), and LV function/remodeling (deter-
mined by echocardiography). In addition to the clinical
outcomes, time to death or heart replacement therapy was
assessed at 6 months (70). Three separate dosing regimens
of AAVI/SERCA2a were tested and compared to a placebo
group, with the high-dose group showing improvement or
stabilization in each of the efﬁcacy endpoints for the
6-month primary analysis. AAV1/SERCA2a was well
tolerated with no reported adverse events (70). The study
was limited by a small sample size and required screening of
over 500 patients due to the presence of cross-reacting
neutralizing antibodies to the viral vector capsid. The
CUPID trial demonstrates that SERCA2a is a potential
therapeutic target in patients with heart failure and provides
supportive evidence for additional, larger randomized trials.
Two clinical trials are currently targeting SERCA2a, one in
patients implanted with left ventricular assist devices and
another examining the effect on cardiac remodeling.Istaroxime. Istaroxime is a novel intravenous drug that
both inhibits the activity of sodium-potassium ATPase and
stimulates sarcoplasmic reticulum calcium ATPase isoform
2a (SERCA2a) (75). This dual mechanism of action results
in Istaroxime having both inotropic action by allowing the
accumulation of cytosolic calcium during contraction and a
lusitropic effect (improvement in diastolic relaxation) by
sequestering calcium during relaxation (75). In an ischemic
chronic heart failure animal model, Istaroxime improved
both systolic and diastolic dysfunction without an increased
incidence of arrhythmias (76). The HORIZON-HF (He-
modynamic, Echocardiographic, and Neurohormonal Ef-
fects of Istaroxime, a Novel Intravenous Inotropic and
Lusitropic Agent: a Randomized Controlled Trial in Pa-
tients Hospitalized with Heart Failure) study assessed the
hemodynamic effects of Istaroxime in a double-blind, pla-
cebo-controlled phase II trial in patients hospitalized with
acute heart failure (75). The primary end point, reduction in
pulmonary capillary wedge pressure, was improved for all 3
doses compared to placebo. A particularly notable secondary
end point was a dose-dependent reduction in heart rate, a
distinguishing feature from traditional intravenous ino-
tropes. Additionally, there was an increase in systolic blood
pressure but no effect on neurohormones, renal function, or
troponin levels (75). Istaroxime is intriguing as a potential
inotrope which avoids the adverse effects associated with
conventional inotropic agents.
Selection of Patients for Home Inotropic Support
Patient preferences and goals of care should ideally be
determined prior to any initiation of intravenous inotropic
therapy. This should involve direct conversations with the
patient and family discussing the available treatment options
and possible outcomes. Various potential scenarios should be
outlined such that expectations are established. For many
Francis et al. JACC Vol. 63, No. 20, 2014
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2076patients who are under consideration for inotropic agent
therapy (milrinone or dobutamine), these discussions cannot
be performed with the patient, as the patient may be too ill
to participate in the discussion. In these cases, surrogate
decision makers should be involved.
When one is unable to wean patients from inotropic
support, many questions arise regarding its continued use.
Discharging a patient with home inotropic therapy is com-
plex and requires that the care team readdresses the goals
developed during the acute use of inotropic agents while
outlining discrete goals prior to discharge. Patients should
also be instructed that further hospitalization is likely even
with home inotropic therapy. For patients awaiting trans-
plant, inotropes are meant to maintain hemodynamics and
end-organ function and alleviate symptoms as a bridge to
transplantation. For patients who are not likely to undergo
further advanced therapies, inotropic agents may alleviate
symptoms and should be provided based on the patient and
family’s preferences in close collaboration with hospice or
end-of-life services (77).
Conclusions
End-stage heart failure is a progressive disease with high
mortality and limited medical therapeutic options. Long-
term use of conventional inotropic agents has been asso-
ciated with no improvement or even increased overall
mortality. This uncomfortable dilemma has led to expanded
use of heart replacement therapy. Development of novel
inotropes has been hindered in recent decades by the ambi-
tious goal of achieving two seemingly opposing effects with a
single molecule. Clinicians want to use drugs that increase
cardiac output without increasing myocardial oxygen con-
sumption. The inotropes in use in the United States today
primarily increase cardiac output by amplifying the natural
pathways for calcium entry into the cell. Calcium handling
is energy intensive leading to adverse effects. The second
goal of newly developed inotropes is to maintain stable levels
of, or even reduce, myocardial energy consumption. The
conserved energy may then be redirected for cellular repair
and promotion of mitochondrial health with reduction of
oxidative stress. Effectively, this requires that the inotropic
agent does not result in increased chronotropy or calcium
ﬂux, as these processes may be the primary cause of the in-
creased mortality associated with inotropic drugs. One would
hope that the next generation of inotropic agents will achieve
enhanced myocardial performance without altering the ve-
locity of shortening or promoting excessive calcium modu-
lation at the level of the SR or the L-type calcium channel.
New agents are on the horizon. However, the methods
used to investigate their safety and efﬁcacy can be chal-
lenging. Patients with end-stage heart failure are unstable
by deﬁnition, thus presenting many additional challenges.
These patients are also highly complex medically, providing
multiple opportunities for confounding inﬂuences. Large
patient populations are usually necessary to test survivaloutcomes. Clinical trials in this group of patients are likely
to continue to be expensive, difﬁcult, and uncertain with
regard to proper end points. Nevertheless, the search for
ideal inotropes should and will continue.
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